Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News information

Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon

2020-02-26
|
Page View:

Guangzhou Magpie Pharmaceuticals announced the clinical trials of MN-08, a treatment for Idiopathic Pulmonary Artery Hypertension (IPAH).  IPAH is a progressive disease that affects the precapillary pulmonary vasculature.  IPAH is a rare and fatal disease which has a high mortality rate.

During the collaboration between Magpie Pharmaceuticals and Medicilon, Medicilon completed the research and development of the GMP manufacturing for API.

Relevant newsRelevant news